Tags: J&J | estimates | stock | Wall Street

Johnson & Johnson Results Beat Wall Street Estimates

Tuesday, 16 Apr 2013 08:10 AM

Johnson & Johnson reported better-than-expected first-quarter earnings, as growth of newer medicines for cancer, hepatitis C and blood clots offset declining sales of its treatments for heartburn and attention deficit disorder.

The diversified healthcare company said on Tuesday it earned $3.5 billion, or $1.22 per share, compared with $3.91 billion, or $1.41 per share, in the year-earlier quarter.

Excluding special items, J&J earned $1.44 per share. Analysts, on average, expected $1.40 per share, according to Thomson Reuters I/B/E/S.

Global company sales rose 8.5 percent to $17.50 billion, slightly higher than the $17.42 billion expected by Wall Street. They would have risen by 9.8 percent if not for the stronger dollar, which hurts the value of sales in overseas markets.

J&J stuck to its earlier full-year 2013 profit forecast of $5.35 to $5.45 per share. It earned $5.10 per share last year.

© 2017 Thomson/Reuters. All rights reserved.

 
1Like our page
2Share
Companies
Johnson & Johnson reported better-than-expected first-quarter earnings, as growth of newer medicines for cancer, hepatitis C and blood clots offset declining sales of its treatments for heartburn and attention deficit disorder.
J&J,estimates,stock,Wall Street
141
2013-10-16
Tuesday, 16 Apr 2013 08:10 AM
Newsmax Inc.
 

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
MONEYNEWS.COM
© Newsmax Media, Inc.
All Rights Reserved